ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 5 of 233 for:    Recruiting, Not yet recruiting, Available Studies | "Hodgkin Disease"

Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE (BV-ICE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02686346
Recruitment Status : Recruiting
First Posted : February 19, 2016
Last Update Posted : March 12, 2018
Sponsor:
Collaborator:
Millennium Pharmaceuticals, Inc.
Information provided by (Responsible Party):
The Lymphoma Academic Research Organisation

Brief Summary:

This study is designed as a phase Ib/II trial. The first part (phase Ib) is a dose escalation design to explore the safety and assess the recommended phase 2 dose of Brentuximab Vedotin in Hodgkin lymphoma patients treated with ICE regimen.

The second part, depending on the selected dose after the completion of phase Ib part of the study, will further explore safety in addition to efficacy of the recommended dose of Brentuximab Vedotin in a selected population of patients treated with ICE with Hodgkin lymphoma.


Condition or disease Intervention/treatment Phase
Hodgkin Disease Drug: Brentuximab Vedotin Drug: Etoposide Drug: Carboplatine Drug: Ifosfamide Phase 1 Phase 2

Detailed Description:

PHASE I:

3 cycles of Brentuximab Vedotin ICE every 3 weeks and one cycle of Brentuximab Vedotin alone at the doses described below.

Cohorts of between three and six evaluable patients will be recruited at each dose level.

Dose escalation rules:

Treat 3 patients at level K

  1. If 0 patients experience dose-limiting toxicity (DLT), escalate to dose K+1
  2. If 2 or more patients experience DLT, de-escalate to level K-1
  3. If 1 patient experiences DLT, treat 3 more patients at dose level K A. If 1 of 6 experiences DLT, escalate to dose level K+1 B. If 2 or more of 6 experiences DLT, de-escalate to level K-1 Dose escalation will begin at level K.

Level K:

Brentuximab Vedotin: 1.2 mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide 100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2)

Level K -1:

Brentuximab Vedotin: 0.8 mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide 100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2)

Level K +1:

Brentuximab Vedotin: 1.8 mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide 100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2)

Dose finding rule:

Provisional dose levels are listed in previous tables. Dose-escalation will continue until Maximal Tolerated Dose (MTD) or Recommended Phase 2 Dose (RP2D) is reached or the full doses of BV and ICE are delivered without DLT

PHASE II:

3 cycles of Brentuximab Vedotin + ICE every 3 weeks and one cycle Brentuximab Vedotin alone.

The recommended dose of BV and ICE will be determined by the phase I Brentuximab Vedotin: MTD mg/kg (cycle 1-3), 1.8 mg/kg (cycle 4) ICE (cycle 1-3): Etoposide 100 mg/m² (day1 to 3); Carboplatine max 800mg (day 2); Ifosfamide + Mesna 5 g/m² (day 2) The recommended dose of BV and ICE will be determined by the phase I.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 55 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I/II Feasibility Study of Brentuximab Vedotin in Refractory / Relapsed Hodgkin Lymphoma Patients Who Are Treated by Chemotherapy (ICE) in Second Line and Eligible for Autologous Transplantation
Actual Study Start Date : March 2016
Estimated Primary Completion Date : July 2018
Estimated Study Completion Date : July 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: BV-ICE

Phase I:

4 cycles of treatment, every 21 days: Brentuximab Vedotin (BV) + Etoposide- Carboplatine - Ifosfamide (ICE) = BV-ICE for cycles 1 to 3 and BV alone at cycle 4;

Phase II:

4 cycles of treatment, every 21 days: BV-ICE for cycles 1 to 3, BV alone at cycle 4

Drug: Brentuximab Vedotin

Phase I:

Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)

Phase II:

BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I

Other Names:
  • BV
  • SGN35

Drug: Etoposide
100 mg/m² Days 1-2-3 of Cycles 1-2-3

Drug: Carboplatine
max 800mg Day 2 of Cycles 1-2-3

Drug: Ifosfamide
5 g/m² Day 2 of Cycles 1-2-3




Primary Outcome Measures :
  1. Phase I : Maximal Tolerated Dose (MTD) determination [ Time Frame: 4 months ]
    To determine the MTD and/or Recommended Phase II dose (RP2D dose) of BV when administered to adult patients treated with ICE in refractory or relapsed Hodgkin's lymphomas.

  2. Phase II = fraction of responding patients according to Lugano classification (metabolic Complete Response) [ Time Frame: 2 months ]
    To evaluate the efficacy of BV in patient treated with ICE as first salvage treatment (establish the fraction of responding patients - metabolic Complete Response (CR)) as judged by the center by Lugano classification after the second cycle


Secondary Outcome Measures :
  1. Phase I : Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 4 months ]
    To characterize the safety and tolerability of BV in patient treated with ICE.

  2. Phase I = Preliminary Overall Response Rate (ORR) [ Time Frame: 4 months ]
    To assess preliminary anti-tumor activity of BV in patient treated with ICE.

  3. Phase II = ORR [ Time Frame: 4 months ]
    To assess the ORR (Complete Response and Partial Response) after 3 cycles of BV and ICE and one cycle of BV

  4. Phase II : Number of participants with treatment-related adverse events as assessed by CTCAE v4.03 [ Time Frame: 4 months ]
    To assess the toxicity profile of BV in patient treated with ICE

  5. Phase II = number of patients with hematological recovery after each cycle [ Time Frame: 4 months ]
    To assess hematological recovery after each cycle of BV and ICE

  6. Phase II = Feasibility of Autologous Stem Cell Transplant (ASCT) after BV-ICE = fraction of patients for whom harvest is possible [ Time Frame: 4 months ]
    To assess the feasibility of harvesting an autologous peripheral blood stem cell graft after BV in patient treated with ICE

  7. Phase II = Fraction of patients eligible for ASCT [ Time Frame: 4 months ]
    To assess the fraction of patients (Complete Response/Partial Response) eligible for ASCT who actually underwent one or two ASCT

  8. Phase II = Number of patients Positron Emission Tomography (PET) 4- after PET 2+ [ Time Frame: 4 months ]
    To assess the number of patients with PET 4 negative if the PET 2 is positive

  9. Phase II = Progression Free Survival (PFS) [ Time Frame: 2 years ]
    Number of participants who did not progressed after 2 years

  10. Phase II = Overall Survival (OS) [ Time Frame: 2 years ]
    Number of participants alive after 2 years



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed cluster of differentiation antigen 30 + (CD30+) HL, primarily refractory to first line chemotherapy or in first relapse after any polychemotherapy regimen
  • Measurable disease defined as at least one single node or tumor lesion on CT scan > 1.5 cm
  • Fluorodeoxyglucose (FDG)-PET/ CT realized at relapse and positive.
  • Age ≥ 18 years and up to 65 years
  • Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2 (see appendix 19.5)
  • Life expectancy of > 3 months with treatment
  • No major organ dysfunction, unless HL-related
  • Normal cardiac and pulmonary function for auto transplantation
  • Total bilirubin < 1.5 x ULN (unless due to lymphoma involvement of the liver or a known history of Gilbert's syndrome)
  • Alanine aminotransferase/aspartate aminotransferase (ALT/AST) ≤ 2 x ULN (unless due to lymphoma involvement of the liver : ≤ 5 x ULN)
  • Creatinine clearance > 60 mL/min
  • Absolute neutrophil count ≥ 1.5x109/L, unless caused by diffuse bone marrow infiltration by the HL
  • Platelets ≥ 100x109/L, unless caused by diffuse bone marrow infiltration by the HL
  • Hemoglobin must be ≥ 8g/dL
  • Written informed consent
  • Able to adhere to the study visit schedule and other protocol requirements
  • Eligible for high dose chemotherapy and autologous peripheral blood stem cell transplantation
  • Resolution of toxicities from first-line therapy
  • Female patient is either post-menopausal for at least 1 year before the screening visit or surgically sterile or if of childbearing potential, agree to practice 2 effective methods of contraception, at the same time, from the time of signing the informed consent through 6 months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse.
  • Male patients, even if surgically sterilized, (i.e., status post vasectomy) agree to practice effective barrier contraception during the entire study period and through 6 months after the last dose of study drug, or agrees to completely abstain from heterosexual intercourse.

Exclusion Criteria:

  • Peripheral sensory or motor neuropathy grade ≥ 2
  • Any chemotherapy, radiotherapy, immunotherapy or investigational, therapy for treatment of lymphoma within 28 days prior Cycle1 Day1
  • Patient who have been treated by first line of treatment with brentuximab vedotin alone or in combination
  • Female patients who are both lactating and breast feeding or have a positive serum pregnancy test during the screening period or a positive pregnancy test 4 days prior the start of study drug
  • Patients with active, uncontrolled infections (requiring systemic antibiotics within two weeks prior to treatment)
  • Prior history of another cancer unless the subject has been free of the disease for ≥ 3 years (with the exception of non-melanoma skin cancer, completely resected melanoma TNMpT1 or carcinoma in situ of the uterine cervix)
  • Known cerebral or meningeal disease (HL or any other etiology), including signs or symptoms of Progressive multifocal leukoencephalopathy
  • Known hypersensitivity to recombinant proteins, murine proteins, or to any excipient contained in the drug formulation of brentuximab vedotin.
  • Known history of human immunodeficiency virus (HIV), or known active Hepatitis C Virus, or active Hepatitis B Virus (HBV) infection or any uncontrolled active systemic infection requiring intravenous (IV) antibiotics.
  • Patients with a psychiatric disorder that would preclude compliance with drug delivery
  • Patients who have any severe and/or uncontrolled medical condition or other conditions that could affect their participation in the study such as:

    1. unstable angina pectoris, symptomatic congestive heart failure (NYHA II, III, IV), myocardial infarction ≤ 2 years prior to first study drug administration, serious uncontrolled cardiac arrhythmia, angina, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities
    2. cerebrovascular accident ≤ 6 months before study drug start recent evidence (within 6 months before first dose of study drug)
    3. a left-ventricular ejection fraction <50%
    4. severely impaired pulmonary function as defined as spirometry and diffusing capacity of the lung for carbon monoxide (DLCO) that is 50% or less of the normal predicted value and/or O2 saturation that is 90% or less at rest on room air
    5. any active (acute or chronic) or uncontrolled disorders that impair the ability to evaluate the patient or for the patient to complete the study
    6. any active systemic viral, bacterial, or fungal infection requiring systemic antibiotics within 2 weeks prior to first study drug dose
    7. nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by this study drug, such as severe hypertension that is not controlled with medical management and thyroid abnormalities when thyroid function cannot be maintained in the normal range

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02686346


Contacts
Contact: Alexia Schwartzmann alexia.schwartzmann@lysarc.org

Locations
Belgium
Clinique Universitaire Saint-Luc Terminated
Bruxelles, Belgium, 1200
CHU Dinant Godinne Recruiting
Yvoir, Belgium, 5530
Contact: Marc ANDRE, MD    0032 81 42 38 64    marc.andre@uclouvain.be   
France
Institut d'Hématologie de Basse Normandie - CHU Côte de Nacre Recruiting
Caen, France, 14033
Contact: Anne-Claire GAC-BESNARD, MD    02 31 06 50 14    gac-ac@chu-caen.fr   
APHP-Hôpital Henri Mondor Recruiting
Créteil, France, 94010
Contact: Fabien LE BRAS, MD    +33 1 49 81 43 20    fabien.le-bras@aphp.fr   
Contact: Feriel BOUABBAS, CRA    +33 1 49 81 43 20    feriel.bouabbas@aphp.fr   
CHU de Dijon - Hôpital le Bocage Recruiting
Dijon, France, 21000
Contact: Olivier CASASNOVAS, MD    03 80 29 50 41    olivier.casasnovas@chu-dijon.fr   
CHRU Lille - Hôpital Claude Huriez Recruiting
Lille, France, 59037
Contact: Franck MORSCHHAUSER, MD    03 20 44 60 68    f-morschhauser@chru-lille.fr   
Centre Léon Bérard Recruiting
Lyon, France, 69373
Contact: Emmanuelle NICOLAS-VIRELIZIER, MD    04 78 78 26 84    emmanuelle.nicolas@lyon.unicancer.fr   
CHU de Montpellier Recruiting
Montpellier, France, 34295
Contact: Philippe QUITTET, MD    03 67 33 83 66    p-quittet@chu-montpellier.fr   
CHU Saint Eloi Recruiting
Montpellier, France, 34295
Contact: Noémie COIGNART, CRA    04 67 33 24 54    n-coignart@chu-montpellier.fr   
Contact: Véra SABADASH, CRA    04 67 33 24 54    v-sabadash@chu-montpellier.fr   
Principal Investigator: Philippe QUITTET, MD         
Sub-Investigator: Guillaume CARTRON, MD         
Sub-Investigator: Robert NAVARO, MD         
Sub-Investigator: Yosr HICHRI, MD         
Sub-Investigator: Laure VINCENT, MD         
CHU De Nantes Recruiting
Nantes, France, 44093
Contact: Thomas GASTINNE, MD       thomas.gastinne@chu-nantes.fr   
APHP - Hôpital Saint Louis Recruiting
PARIS Cedex 10, France, 75475
Contact: Armelle VILAIN, CRA    01 42 49 49 49    armelle.vilain@sls.aphp.fr   
Contact: Nadia HARROUCHE, CRA    01 42 49 49 49    nadia.hadouche@sls.aphp.fr   
Principal Investigator: Pauline BRICE, MD         
Sub-Investigator: Catherine THIEBLEMONT, MD         
Sub-Investigator: Stéphanie HAREL, MD         
Sub-Investigator: Sandy AMORIN, MD         
Hôpital Necker Recruiting
Paris, France, 75015
Contact: Richard DELARUE, MD    01 44 49 54 16    richard.delarue@aphp.fr   
CH Haut-Lévêque - Centre François Magendie Recruiting
Pessac, France, 33604
Contact: Kamal-Krimo BOUABDALLAH, MD    05 57 65 65 11    krimo.bouabdallah@chu-bordeaux.fr   
CHU Lyon Sud Recruiting
Pierre Bénite Cedex, France, 69495
Contact: Virginie TRONCHON, MD       virginie.tronchon@chu-lyon.fr   
Principal Investigator: Gilles SALLES, MD         
Sub-Investigator: Bertrand COIFFIER, MD         
Sub-Investigator: Fadhela BOUFFIA-SAUVY, MD         
Sub-Investigator: Daniel ESPINOUSSE, MD         
Sub-Investigator: Anne-Sophie MICHALLET, MD         
Sub-Investigator: Laure LEBRAS, MD         
Sub-Investigator: Lionel KARLIN, MD         
Sub-Investigator: Marie BOUTELOUP, MD         
Sub-Investigator: Emmanuel BACHY, MD         
CHU de Poitiers - Hôpital de La Milétrie Recruiting
Poitiers, France, 86021
Contact: Stéphanie GUIDEZ, MD    05 49 44 46 89    stephanie.guidez@chu-poitiers.fr   
CHU De Rennes Recruiting
Rennes, France, 35033
Contact: Thierry LAMY DE LA CHAPELLE, MD    02 99 28 93 12    thierry.lamy.de.la.chapelle@chu-rennes.fr   
Centre Henri Becquerel Recruiting
Rouen, France, 76000
Contact: Delphine ROBBE, CRA       delphine.robbe@chb.unicancer.fr   
Principal Investigator: Aspasia STAMATOULLAS - BASTARD, MD         
Sub-Investigator: Oana BREHAR, MD         
Sub-Investigator: Fabrice JARDIN, MD         
Sub-Investigator: Stéphane LEPRETRE, MD         
Sub-Investigator: Hervé TILLY, MD         
Sub-Investigator: Pascal LENAIN, MD         
Sub-Investigator: Nathalie CONTENTIN, MD         
Sub-Investigator: Emilie LEMASLE, MD         
Sub-Investigator: Marie-Laure FONTOURA, MD         
Sub-Investigator: Carole FRONVILLE, MD         
Sub-Investigator: Nathalie CARDINAEL, MD         
Sub-Investigator: Hélène LANIC, MD         
Sub-Investigator: Ophélie CASSUTO, MD         
CHU De Strasbourg Recruiting
Strasbourg, France, 67098
Contact: Luc-Mathieu FORNECKER, MD    03 88 12 76 67    luc-matthieu.fornecker@chru-strasbourg.fr   
IUCT Toulouse Recruiting
Toulouse, France, 31100
Contact: Cécile BOREL, MD    05 31 15 61 91    borel.cecile@iuct-oncopole.fr   
CHU De Nancy - Hôpital Brabois Recruiting
Vandœuvre-lès-Nancy, France, 54511
Contact: Aurore PERROT, MD    03 83 15 32 82    au.perrot@chru-nancy.fr   
Institut Gustave Roussy Not yet recruiting
VILLEJUIF Cedex, France, 94085
Contact: Wassila RAHALI, CRA    01 42 11 66 08    wassila.rahali@gustaveroussy.fr   
Principal Investigator: Vincent RIBRAG, MD         
Sub-Investigator: Christophe FERME, MD         
Sub-Investigator: Christian BOURHIS, MD         
Sub-Investigator: David GHEZ, MD         
Sub-Investigator: Stéphane DE BOTTOM, MD         
Sub-Investigator: WITTNEBEL, MD         
Sub-Investigator: MICOL, MD         
Sub-Investigator: Alina DANU, MD         
Sub-Investigator: Julien LAZAROVICI, MD         
Institut Gustave Roussy Recruiting
Villejuif, France, 94085
Contact: Vincent RIBRAG    01 42 11 66 08    vincent.ribrag@gustaveroussy.fr   
Sponsors and Collaborators
The Lymphoma Academic Research Organisation
Millennium Pharmaceuticals, Inc.
Investigators
Principal Investigator: Pauline Brice, MD Lymphoma Study Association
Principal Investigator: Aspasia Stamatoullas Bastard, MD Lymphoma Study Association

Responsible Party: The Lymphoma Academic Research Organisation
ClinicalTrials.gov Identifier: NCT02686346     History of Changes
Other Study ID Numbers: BV-ICE
First Posted: February 19, 2016    Key Record Dates
Last Update Posted: March 12, 2018
Last Verified: March 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by The Lymphoma Academic Research Organisation:
Relapsed
Refractory

Additional relevant MeSH terms:
Hodgkin Disease
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Etoposide
Etoposide phosphate
Isophosphamide mustard
Ifosfamide
Antibodies, Monoclonal
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Alkylating
Alkylating Agents
Immunologic Factors
Physiological Effects of Drugs